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Abstract
Introduction: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by sustained
synovitis. Recently, several studies have proposed neutrophils and Th17 cells as key players in the onset and
perpetuation of this disease. The main goal of this work was to determine whether cytokines driving neutrophil
and Th17 activation are dysregulated in very early rheumatoid arthritis patients with less than 6 weeks of disease
duration and before treatment (VERA).
Methods: Cytokines related to neutrophil and Th17 activation were quantified in the serum of VERA and
established RA patients and compared with other very early arthritis (VEA) and healthy controls. Synovial fluid (SF)
from RA and osteoarthritis (OA) patients was also analyzed.
Results: VERA patients had increased serum levels of cytokines promoting Th17 polarization (IL-1b and IL-6), as
well as IL-8 and Th17-derived cytokines (IL-17A and IL-22) known to induce neutrophil-mediated inflammation. In
established RA this pattern is more evident within the SF. Early treatment with methotrexate or corticosteroids led
to clinical improvement but without an impact on the cytokine pattern.
Conclusions: VERA patients already display increased levels of cytokines related with Th17 polarization and
neutrophil recruitment and activation, a dysregulation also found in SF of established RA. 0 Thus, our data suggest
that a cytokine-milieu favoring Th17 and neutrophil activity is an early event in RA pathogenesis.
Introduction
Rheumatoid arthritis (RA), the most common chronic
autoimmune disease, affects approximately 1% of the
population worldwide. This disease comprises a syn-
drome of pain, stiffness, and symmetrical synovitis
which leads to joint destruction, functional disability,
and substantial comorbidity due to the involvement of
multiple organs and systems. The migration of leuko-
cytes toward the synovium is crucial for the establish-
ment of a chronic inflammatory process in RA [1-3].
This multi-regulated mechanism involves interactions
with endothelial cells through cell adhesion molecules
and complex cytokine and chemokine pathways.
Neutrophils specifically play an important role in the
onset and perpetuation of RA, not only as interleukin
(IL)-producing cells but also as cells responsible for the
release of high amounts of reactive oxygen species and
destructive enzymes, such as metalloproteases, contri-
buting to joint erosions [4]. Neutrophils are among the
first leukocytes to arrive at sites of inflammation. In
fact, these cells are the most abundant in the synovial
fluid (SF) of patients with active RA, and previous
results from our group showed that the synovial tissue
is heavily infiltrated by neutrophils in the first weeks of
RA onset [5]. Interestingly, in animal models of arthritis,
neutrophil depletion prevented joint inflammation if
neutrophil-depleting antibodies were given before the
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induction of arthritis. Moreover, when the depleting
antibody was given very early after the induction of
arthritis, complete abrogation of the inflammatory
symptoms was achieved [6].
T helper 17 (Th17) cells have also been proposed to
have a relevant role in the early phase of RA through
the production of IL-17 [7,8]. This cytokine promotes
the recruitment and survival of neutrophils, induces the
secretion of proinflammatory cytokines and the upregu-
lation of RANKL (receptor activator of nuclear factor-
kappa B ligand), and stimulates the activity of matrix
metalloproteases, leading to cartilage catabolism and
bone resorption [9,10]. The recruitment, activation, and
effector function of Th17 cells and neutrophils are dri-
ven by a network of cytokines and chemokines secreted
by multiple cellular sources. In established RA, it has
been reported that IL-1b, IL-6, IL-8, IL-17, and tumor
necrosis factor are elevated in the serum and this corre-
lates with a higher disease activity [11-13]. Nevertheless,
our knowledge of the influence of the cytokine network
on RA onset remains limited. The characterization of
the cytokine profile at this stage, where the transition
from an acute to a chronic inflammatory phase occurs,
may lead to the identification of early key players, with
potential implications for early treatment strategies.
Thus, the main goal of our work was to determine
whether cytokines driving neutrophil and Th17 cell acti-
vation and proinflammatory function were already pre-
sent in very early RA (with less than 6 weeks of disease
duration) and how this early cytokine environment dif-
fers from established RA. We also evaluated whether the
introduction of low-dose corticosteroids and methotrex-
ate (MTX) therapy had any influence on the cytokine
profile observed at that early stage of the disease. We
found that cytokines related to Th17 polarization and
neutrophil recruitment and activation were elevated in
early RA and that the conventional therapeutic options,
though able to control clinical manifestations of the dis-
ease, were ineffective in reversing this underlying proin-
flammatory drive.
Materials and methods
Patients
Blood samples were obtained from 38 consecutive
untreated polyarthritis patients with less than 6 weeks of
disease duration. Some of these patients (19), after a
minimum follow-up of 3 months, fulfilled the 1987
American College of Rheumatology (ACR) criteria for
RA [14]. These patients were classified as very early rheu-
matoid arthritis (VERA) patients, and further samples
were collected 4 to 6 weeks after starting a low dose of
oral corticosteroids (5 to 10 mg of prednisone) (time 1)
and 4 months after reaching the minimum effective dose
of MTX (time 2) (up to a maximum of 20 mg/week) that
was required to reduce the disease activity score using 28
joint counts (DAS28) to less than 3.2 [15]. The remaining
early arthritis patients (19), who did not develop RA,
were classified as very early arthritis (VEA). Baseline
blood samples from VERA and VEA patients were com-
pared with 27 healthy donors used as controls. Addition-
ally, 12 blood and 15 SF samples were obtained from
patients with established RA. SF samples were also col-
lected from 10 patients with osteoarthritis (OA) (Rheu-
matology Department, Hospital de Santa Maria, Lisbon,
Portugal) (Table 1). Owing to the clinical characteristics
of the VEA patients, SF in easily accessible joints was not
available in VERA and VEA patients and thus SF was not
analyzed in these groups of patients. The health assess-
ment questionnaire (HAQ) [16] and DAS28 were applied
to all patients. The study was approved by the local ethics
committee, and all patients signed an informed consent
form. Patient care was conducted in accordance with
standard clinical practice, and the study was performed
in accordance with the Declaration of Helsinki as
amended in Edinburgh (2000).
Cytokine quantification
IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12(p70), IL-17A,
IL-22, IL-23, and interferon-gamma levels were mea-
sured in the serum and SF by FlowCytomix assay kit
(Bender MedSystems, Vienna, Austria) in accordance
with the instructions of the manufacturer. Standard
curves for each cytokine were generated by using refer-
ence cytokine concentrations supplied by the manufac-
turer. Samples were acquired with a FACS Calibur flow
cytometer (BD Biosciences, San Jose, CA, USA). Raw
data of the flow cytometry bead assay were analyzed by
FlowCytomix Pro 2.2 software (Bender MedSystems).
Measurement of autoantibodies
Rheumatoid factor (RF)-IgM was determined in all
patients by means of an IMTEC Autoimmune Diagnos-
tics ELISA [enzyme-linked immunosorbent assay] kit
(Human GmbH, Wiesbaden, Germany) in accordance
with instructions of the manufacturer, and samples were
processed using a ChemWell 2910 automated analyzer
(GMI, Ramsey, Minnesota, USA). Serum levels of anti-
cyclic citrullinated peptide (anti-CCP) were measured by
ELIA™ CCP test system (Phadia GmbH, Freiburg, Ger-
many), and samples were analyzed with an ImmunoCAP
100 instrument (Phadia GmbH).
Statistical analysis
Statistical differences were determined with non-
parametric Kruskal-Wallis, Mann-Whitney, and
Wilcoxon signed-rank tests and GraphPad Prism (Graph-
Pad Software, Inc., San Diego, CA, USA). Correlation
analysis was performed with the Spearman test.
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Differences were considered statistically significant for
P values of less than 0.05.
Results
Characterization of patients and disease evaluation
A total of 38 polyarthritis patients with less than 6
weeks of disease duration were evaluated. Nineteen
patients fulfilled the 1987 ACR criteria for RA after a
minimum follow-up of 3 months and were classified as
VERA patients. The mean age of the VERA patients was
59 ± 17 years, 84% were female, 42% were RF-positive
and 32% anti-CCP-positive, the initial DAS28 was 6.1 ±
1.8, and the initial HAQ was 1.4 ± 0.8. After treatment
with low doses of prednisone and MTX, there was a sig-
nificant reduction of both DAS28 and HAQ values
(Table 1). The group of VEA patients included 19
patients, and 14 of them later had one of the following
diagnoses: spondylarthritis (5 cases), systemic lupus
erythematosus (4 cases), crystal induced arthritis (2
cases), Sjögren syndrome (1 case), paraneoplastic polyar-
thritis related to multiple myeloma (1 case), and arthritis
associated with HIV infection (1 case). Five patients
entered spontaneously into remission before 3 months
of follow-up, remaining without a specific diagnosis and
were thus classified as presenting a self-limited form of
polyarthritis. The mean age of the VEA patients was 40
± 13 years, 79% were female, all patients were RF-nega-
tive and anti-CCP-negative, the initial DAS28 was 4.5 ±
1.6, and the initial HAQ was 0.8 ± 0.6. Both DAS28 and
HAQ values were significantly lower than those of
VERA patients at baseline (Table 1). These early polyar-
thritis patients represent a subset of a larger cohort pre-
viously described by our group [17].
Furthermore, blood samples were collected from 12
patients with established RA; mean age was 60 ± 10
years, 92% were female, and 67% were RF-positive and
45% anti-CCP-positive (Table 1). Additionally, SF sam-
ples were collected from 12 patients with established
RA; mean age was 57 ± 10 years, and 73% were female
(Table 1). The established RA group of patients had a
DAS28 and a HAQ mean scores similar to VERA base-
line values.
IL-8 is increased in VERA patients and locally in the joints
of patients with established RA
Given the proposed role of neutrophils in the pathogen-
esis of RA [18,19], we quantified the major neutrophil
chemoattractant, IL-8, in the serum of VERA patients.
At baseline, VERA patients had significantly higher
levels of IL-8 when compared with both VEA and
healthy controls (Figure 1a). After 2 to 4 weeks of low-
dose corticosteroids and after 4 months of MTX ther-
apy, there were no significant changes in the levels of
circulating IL-8 (data not shown). Interestingly, VERA
patients also had significantly higher circulating levels of
IL-8 in comparison with serum from established RA
(Figure 1a). Neutrophils accumulate locally in the joints
of patients with RA [20]. Thus, we quantified the con-
centration of IL-8 in the SF of patients with RA and
compared the concentration with that of SF from
patients with OA. We found significantly higher levels
of IL-8 in the SF of patients with RA in comparison
with OA SF (Figure 1b).
IL-17 levels are dysregulated in both VERA patients and
patients with established RA
Previous studies from our group showed that there is a
delay in the apoptosis of circulating neutrophils in
VERA patients [21]. Therefore, we analyzed IL-17A
levels in these patients since it has already been
described that this cytokine is important for the survival
of neutrophils [22]. Moreover, IL-17A is a signature
cytokine of Th17 cells, a subset proposed to have a key
role in RA pathogenesis [9,23]. We found that VERA
patients had significantly higher levels of IL-17A when
compared with healthy controls, but not with VEA
patients (Figure 2a). Furthermore, in our previous work,
we found no difference in the frequency and absolute
Table 1 Clinical information about healthy controls and patients with VERA, VEA, RA, or OA
Controls
(n = 24)
VERA (n = 19) VEA
(n = 19)
RA
(n = 12)
RA SF
(n = 15)
OA SF
(n = 10)
Baseline Time 1 Time 2
Age in years, mean ± SD 40 ± 13 50 ± 17 40 ± 13 63 ± 10 57 ± 10 67 ± 13
Sex, female/male 17/7 16/3 15/4 11/1 11/4 5/5
DAS28, mean ± SD NA 6.1 ± 1.8 4.1 ± 1.6a 3.1 ± 1.6a 4.5 ± 1.6a 5.2 ± 1.0 4.6 ± 1.4 NA
HAQ, mean ± SD NA 1.4 ± 0.8 0.8 ± 0.7a 0.8 ± 0.7 0.8 ± 0.6a 1.5 ± 1.0 1.4 ± 0.8 NA
RF-positive, % ND 42 ND ND 0 67 ND ND
Anti-CCP-positive, % ND 32 ND ND 0 45 ND ND
aDisease activity score using 28 joint counts (DAS28) and health assessment questionnaire (HAQ) values were compared between very early rheumatoid arthritis
(VERA) and very early arthritis (VEA) patients with reference to VERA baseline values. Differences were considered statistically significant for P values of less than
0.05. anti-CCP, anti-cyclic citrullinated peptide; IL, interleukin; MTX, methotrexate; NA, not applicable; ND, not determined; OA, osteoarthritis; RA, rheumatoid
arthritis; RF, rheumatoid factor; SD, standard deviation; SF, synovial fluid.
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numbers of CD4+ and CD8+ T-cell subpopulations in
the peripheral blood of these patients when analyzed by
flow cytometry [17].
Regarding the effects of early therapy, we found that
neither corticosteroids nor MTX affected the level of
IL-17A (data not shown). Moreover, IL-17A was signifi-
cantly increased locally within the joints of patients with
established RA in comparison with control SF from
patients with OA (Figure 2b).
RA has a Th17-cytokine pattern since the very first weeks
of onset
Having found that IL-17A was elevated in VERA
patients, we decided to quantify a panel of cytokines
known to be associated with Th17 polarization. At base-
line, VERA patients had significantly higher levels of IL-
1b and IL-22 in comparison with both VEA and healthy
controls. In addition, we found that VERA patients have
significantly higher IL-6 levels than healthy controls
(Figure 3). Furthermore, the significantly higher circulat-
ing levels of IL-6 and IL-22 were maintained in estab-
lished RA (Figure 3).
Locally, within the joints of patients with RA, the SF
displayed elevated levels of IL-1b and IL-6 in compari-
son with OA SF (Figure 4 and Table 2). Moreover, no
significant differences could be observed for IL-23 in
circulation or locally in the joints (data not shown). We
have also studied cytokines associated with the function
of Th2 (IL-4 and IL-10) and Th1 (IL-2, IL-12 (p70), and
INFg) cells. However, no statistically significant differ-
ences could be observed for any of these cytokines (data
not shown).
Discussion
Several studies have previously demonstrated that neu-
trophils play an important role in the onset of RA [21].
Figure 1 Interleukin-8 (IL-8) is increased in the serum of very early rheumatoid arthritis (VERA) patients and in synovial fluid (SF) of
established rheumatoid arthritis (RA). (a) The serum concentration of IL-8 was measured in VERA and very early arthritis (VEA) patients as well
as healthy controls and patients with established RA. The serum concentration of IL-8 was increased in VERA patients compared with any other
group. Dotted line represents the limit of detection for the assay. (b) The concentration of IL-8 was measured in the SF collected from patients
with established RA and from a control group with osteoarthritis (OA). We found a significant increase of IL-8 in RA-SF. Differences were
considered statistically significant for P values of less than 0.05 according to the Mann-Whitney test.
Figure 2 Very early rheumatoid arthritis (VERA) patients and synovial fluid (SF) of established rheumatoid arthritis (RA) display
increased levels of interleukin-17A (IL-17A). (a) The serum concentration of IL-17A was measured in VERA and very early arthritis (VEA)
patients as well as healthy controls and patients with established RA. The serum concentration of IL-17A was increased in VERA patients
compared with healthy controls. (b) The concentration of IL-17A was measured in the SF collected from patients with established RA and from
a control group with osteoarthritis (OA). In the SF of patients with RA, we observed a significant increase of IL-17A. Dotted lines represent the
limit of detection for the assay. Differences were considered statistically significant for P values of less than 0.05 according to the Mann-Whitney
test.
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This hypothesis is supported by data from animal mod-
els [24]. In fact, neutrophils are the most abundant leu-
kocytes in the SF of patients with active RA, and in
early RA, these cells show significantly lower levels of
apoptosis when compared with patients with other per-
sistent forms of arthritis or with arthritis that has a self-
limited disease course [25]. Additionally, previous results
from our group demonstrated that there is a delay in
the apoptosis of circulating neutrophils in VERA
patients [21] and that these cells heavily infiltrate the
synovial tissue during RA onset [5].
In the present study, we demonstrate that a neutro-
phil- and Th17-driving cytokine pattern is present in
untreated VERA patients with less than 6 weeks of
Figure 3 Cytokines related to T helper 17 (Th17) polarization are increased in the serum of very early rheumatoid arthritis (VERA)
patients and synovial fluid of established rheumatoid arthritis (RA). The serum concentrations of interleukin (IL)-1b, IL-6, and IL-22 were
measured in VERA and very early arthritis (VEA) patients as well as healthy controls and patients with established RA. All three cytokines were
increased in VERA patients compared with healthy controls. IL-6 was equally elevated in all groups of patients with an inflammatory disease,
whereas the other two cytokines were increased only in VERA (IL-1b) or in VERA and RA patients (IL-22). Dotted lines represent the limit of
detection for the assays. Differences were considered statistically significant for P values of less than 0.05 according to the Mann-Whitney test.
Figure 4 Cytokines related to T helper 17 (Th17) polarization are increased in the synovial fluid (SF) of established rheumatoid
arthritis (RA). The concentrations of interleukin (IL)-1b and IL-6 were markedly increased in the SF collected from patients with established RA
when compared with osteoarthritis (OA). Dotted lines represent the limit of detection for the assays. Differences were considered statistically
significant for P values of less than 0.05 according to the Mann-Whitney test.
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disease duration. We consider this observation of inter-
est because the knowledge concerning the immune
mechanisms associated with the onset of RA is still elu-
sive. In fact, the majority of early RA studies include
patients with 3 to 12 months of disease duration or
even more. In accordance with an early participation of
neutrophils in RA, our results revealed that VERA
patients have increased levels of IL-8 when compared
with both VEA and healthy controls, and this could
explain the preactivated state of circulating neutrophils
[18] and their recruitment toward the SF from the very
first weeks of RA onset.
In addition, Th17 cells are known to be important for
the promotion of neutrophil-mediated inflammation by
producing IL-17A, a cytokine known to indirectly acti-
vate neutrophil chemotaxis and extend their survival
[10,22]. We found a high serum concentration of IL-17A
in VERA patients as well as locally within the joints of
patients with established RA. This might indicate that an
activation of Th17 cells from a very early phase of the
disease can promote neutrophil participation in RA
pathogenesis [22]. However, we found no evidence for
changes in the frequency of T-cell subsets in the periph-
eral blood of VERA patients [17]. This observation is not
unexpected; the relatively small representation of anti-
gen-specific T cells in the circulating pool are the acti-
vated T cells that drive the pathology more likely found
within the tissues [26]. In a study performed by Kokko-
nen and colleagues [27], the levels of several cytokines
and chemokines were analyzed in blood samples from a
group of individuals 3.3 years before RA onset (’pre-
patients’) and compared with healthy donors and RA
patients with 7.7 ± 3.6 months of disease duration. An
interesting finding was that IL-17 was present at its high-
est concentration in pre-patients and the level of this
cytokine was lower in patients with RA. This is in accor-
dance with our own results; we observed an increased
level of IL-17 in RA patients with less than 6 weeks of
disease duration, whereas in patients with established
RA, the levels were not significantly different from those
of healthy controls. Remarkably, the IL-17 median con-
centration observed in our established RA cohort (2.6 pg/
mL) was even lower than that of RA patients from the
work of Kokkonen and colleagues [27] (6.0 pg/mL).
Thus, this observation reinforces the role of IL-17 in the
initial phase of RA, and as the pathogenesis progresses to
a chronic stage, other factors are subsequently brought
into action in the peripheral blood. Unlike Kokkonen and
colleagues, we have not detected differences in Th1- and
Th2-related cytokines between both VERA and patients
with established RA in comparison with controls. These
discrepancies might be related to the different methodol-
ogies used.
Additionally, the elevated levels of IL-1b observed in
VERA patients can stimulate endothelial cells, T and B
cells, and fibroblasts in the joints to produce IL-6 and
IL-8. But importantly, IL-1b and IL-6, both found to be
increased in VERA patients, are known to promote the
differentiation of Th17 cells, which in turn secrete
IL-17A and IL-22 [28,29], two cytokines that were ele-
vated in VERA patients and have an essential function
in the pathogenesis of autoimmune diseases [29].
Currently, the treatment of choice for RA at the time
of presentation is MTX. Interestingly, in spite of clinical
improvement (DAS28 reduced from 6.1 ± 1.8 to 3.1 ±
1.6), neither therapy with low-dose corticosteroids nor
combined therapy with low-dose corticosteroids and
MTX corrected the dysregulated cytokine pattern
observed in VERA patients. In fact, low-dose corticos-
teroids and MTX have unclear effects on the RA cyto-
kine network. For instance, corticosteroids fail to reduce
serum levels of IL-1b and IL-8 [30] and MTX does not
alter serum IL-1b concentration when compared with
pre-treatment levels [31,32]. Our results suggest that the
conditions contributing to Th17 cells and neutrophil-
mediated inflammation, thus driving early pathogenesis,
are not modified with early treatment with low-dose
corticosteroids and MTX.
The elevated IL-1b, IL-6, IL-8, and IL-17A levels
observed in the SF of patients with RA confirm a local
Table 2 Cytokine levels in healthy controls and patients with VERA, VEA, established RA, or OA
Cytokine, pg/mL Controls VERA VEA RA RA SF OA SF
IL-1b 4.2
(4.2-116.8)
17.7
(4.2-99.7)
4.2
(4.2-272.7)
4.2
(4.2-360.3)
6.5
(4.2-322.1)
4.2
(4.2-15.5)
IL-6 1.2
(1.2-7.2)
5.2
(1.2-153.2)
1.2
(1.2-84.7)
8.2
(1.2-19.7)
6361.0
(272.7-24,135.0)
177.6
(46.6-4,881.0)
IL-8 9.9
(0.5-407.7)
57.6
(12.5-1,546.0)
8.9
(0.5-665.2)
15.2
(0.8-67.5)
735.7
(28.3-3,717.0)
48.2
(22.0-680.0)
IL-17A 2.5
(2.5-333.7)
62.0
(2.5-1,714.0)
2.5
(2.5-1,477.0)
2.6
(2.5-375.6)
21.1
(2.5-369.1)
2.5
(2.5-9.5)
IL-22 43.3
(43.3-153.4)
165.3
(43.3-380.6)
43.3
(43.3-270.5)
131.7
(75.8-250.7)
153.4
(75.8-336.0)
151.7
(92.4-235.3)
Values are presented as median (range). IL, interleukin; OA, osteoarthritis; RA, rheumatoid arthritis; SF, synovial fluid; VEA, very early arthritis; VERA, very early
rheumatoid arthritis.
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role for these cytokines in the maintenance of synovitis.
Moreover, IL-6 can support a continuous recruitment of
autoreactive B cells toward the synovium [33,34], contri-
buting to an exacerbation of the inflammatory process
because of the production of autoantibodies and
immune complexes.
Conclusions
Taken together, our data reinforce the potential rele-
vance of therapies targeting IL-1b [35,36] and IL-6
[37,38] in early RA. In addition, the data establish IL-8
and IL-17A as other potential therapeutic targets at an
early stage of the disease. Finally, we found that MTX
and corticosteroids, though effective in reducing disease
activity in VERA patients, do not appear to correct
underlying cytokine dysregulation driving the Th17/neu-
trophil-mediated inflammation.
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